BDX — Becton, Dickinson and Company
Is BDX overbought or oversold? Here is the current MarketMoodz read.
Becton, Dickinson and Company (BDX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $215.42. The rating moved from Neutral to Overbought on November 13, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$215.42
- Last changeMoved from Neutral to Overbought on November 13, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all overbought Healthcare stocks →
AI analysis
Becton, Dickinson and Company (BDX) benefits from a diversified medtech franchise with high-margin recurring consumables and a large installed base that supports steady cash flow. Current thematic drivers — including expansion of robotic-assisted surgery and continued specialty distribution flows — present incremental upside through higher consumable attach rates and service revenue. The company’s scale and balance-sheet flexibility enable ongoing R&D investment and selective M&A to extend addressable markets. Near-term performance will track global procedure volumes, hospital capital spending, and reimbursement dynamics. Key challenges include competitive pressure from new robotic platforms, regulatory/reimbursement uncertainty, and operational execution (quality and supply chain). Overall outlook favors stable top-line and margin resilience, with upside from stronger procedure recovery and successful integration of strategic initiatives.
Key factors
- Diversified medtech portfolio spanning diagnostics, medical devices and biosciences with recurring consumables and replacement revenue
- Strong installed base and long product lifecycles that support durable aftermarket and consumables revenue
- Exposure to surgical/imaging/infusion markets that benefit from secular growth in procedural volumes and chronic-care management
- Surgical robotics expansion and broader adoption of advanced OR platforms can increase consumable attach rates and service revenue
- Defensive demand patterns and flows into large-cap healthcare reduce cyclicality in market selloffs
- Historically solid cash generation and balance-sheet flexibility to invest in R&D, tuck-in M&A, and share repurchases
Risks
- Procedure volume sensitivity — prolonged elective surgery slowdowns or lower hospital utilization would pressure sales
- Reimbursement and payer pressure, including regulatory changes in Medicare/Medicaid that could affect hospital and provider purchasing
- Competitive threats from surgical robotics providers, new entrants, or lower-cost rivals in core consumables
- Product quality, recalls or supply-chain disruptions that could hit revenue and gross margins
- Currency and macro pressures (hospital capital budgets, labor inflation) that can compress margins and slow adoption
- Integration and execution risk for acquisitions or large strategic initiatives
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.